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984Objective: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non–small
cell lung cancer (NSCLC). However, there are a large number of MMP subtypes with diverse proteolytic sub-
strates and different induction pathways. This study tested the hypothesis that a differential MMP profile would
exist between NSCLC and normal lung and that MMP patterns would differ between NSCLC histologic types.
Methods: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC
with either squamous cell (n ¼ 22) or adenocarcinoma (n ¼ 19) histologic characteristics. Absolute concentra-
tions for each of the MMP subclasses were determined by a calibrated and validated multiplex suspension array:
collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), lysins (MMP-2 and -7), and elastase (MMP-12).
Results: Overall, MMP levels were significantly increased in NSCLC compared with normal. For example,
MMP-1 and MMP-7 increased by approximately 10-fold in NSCLC (P<.05). Moreover, a different MMP port-
folio was observed between NSCLC histologic types. For example MMP-1, -8, -9, and -12 increased by more than
4-fold in squamous cell versus adenocarcinoma (P<.05). In those patients who had recurrence within 3 years of
resection, 3-fold higher levels of MMP-8 and -9 were observed (P< .05).
Conclusion: Increased levels of a number of MMP types occur with NSCLC, but the MMP profile was distinctly
different between histologic types and in those patients with recurrence. These different MMP profiles may be
important in the mechanistic basis for the natural history of different NSCLC types, as well as identifying poten-
tial prognostic and therapeutic targets. (J Thorac Cardiovasc Surg 2010;139:984-90)Matrix metalloproteinases (MMPs) are a large family of
structurally and functionally related zinc endopeptidases
that collectively can degrade virtually all extracellular ma-
trix components and can regulate the tumor microenviron-
ment through processing substrates including growth
factors and their receptors, cell adhesion molecules, cyto-
kines, chemokines, apoptotic ligands, and angiogenic fac-
tors.1,2 The potential role and regulation of MMPs have
been the subject of a number of past studies in lung can-
cer.1-12 However, these past studies usually focused on a sin-
gle MMP type or class, and therefore the pattern of MMP
expression in lung cancer remained poorly understood.
Moreover, although the diversity and complexity of the
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The Journal of Thoracic and Cardiovascular Surgstrategy for MMPs in the context of cancer therapeutics
was that of broad-spectrum, global MMP inhibitors.13-16
These initial broad-spectrum MMP inhibitors were not suc-
cessful, and the underlying reasons for this were multifacto-
rial and likely included poor specificity and adverse side
effects. One outcome from these past MMP pharmacologic
studies was the recognition that more targeted therapeutic
approaches would be required. Thus, studies that more care-
fully quantify a more diverse number of MMPs in the con-
text of cancer, such as non–small cell lung cancer
(NSCLC), are warranted. Accordingly, the overall goal of
the present study was to quantify a large number of MMP
types, from different MMP classes, in samples taken from
NSCLC and compare these with normal regions from the
same patient. Moreover, this study examined whether and
to what degree different MMP portfolios would emerge in
NSCLC of different histologic types and in patients with
early recurrence.
MATERIALS AND METHODS
Patients
Snap-frozen lung specimens were taken from the targeted resection re-
gion from patients with either stage I or II NSCLC (22 squamous cell; 19
adenocarcinoma) or from the remote, normal region. These samples were
retained under cryogenic conditions in the Hollings Cancer Center, Medical
University of South Carolina tissue repository. The adenocarcinoma cohort
consisted of 16 patients with stage I and 3 patients with stage II (4 men; 15
women). The squamous cell cohort included 16 patients with stage I and 6
patients with stage II (18 men, 4 women). Before tissue sampling at the timeery c April 2010
TABLE 1. Multiplex matrix metalloproteinase (MMP) antisera and
sensitivity
Analyte Manufacturer Catalog no. Sensitivity
MMP-1 R&D Systems LMP901 4.44 pg/mL
MMP-2 R&D Systems LMP902 25.4 pg/mL
MMP-3 R&D Systems LMP513 1.3 pg/mL
MMP-7 R&D Systems LMP907 16.9 pg/mL
MMP-8 R&D Systems LMP908 8.9 pg/mL
MMP-9 R&D Systems LMP911 7.4 pg/mL
MMP-12 R&D Systems LMP919 1.2 pg/mL
MMP-13 R&D Systems LMP511 15.9 pg/mL
MMP-2 (ng)
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FIGURE 1. A representative 5-parameter logistic (5-PL) curve developed
for MMP-2 using a wide range of MMP-2 recombinant control standards
(black circles). The 5-PL uses the equation where y ¼ dþ (ad)/(1þ (x/
c)^b)^g), in which x¼ concentration of standard, y is the response variable,
a is the estimated response at 0 concentration, b is the slope of the tangent
midpoint, c is the midrange of concentration or midpoint, d is the estimated
response at infinite concentration, and g is an asymmetry factor. This non-
linear regression fitting is optimal for response variables such as fluores-
cence emission.22 The lung samples that were loaded using identical
protein concentrations (gray circles) all fell within the dynamic range of
the standards and the 5-PL equation.
Abbreviations and Acronyms
MMP ¼ matrix metalloproteinase
NSCLC ¼ non–small cell lung cancer
TIMP ¼ tissue inhibitors of the matrix
metalloproteinase
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sue banking purposes, and this specific study was approved by the Institu-
tional Review Board of the Medical University of South Carolina,
Charleston, South Carolina (HR# 18229). The data obtained from these
banked samples included the histologic type (squamous cell carcinoma, ad-
enocarcinoma) as well as whether recurrence had occurred within 3 years of
the initial resection. Recurrence was defined as locoregional (recurrence of
tumor within the lung or mediastinal lymph nodes ipsilateral to the side of
surgery) or distant.
Sample Preparation
The lung samples were processed in a simultaneous fashion using a ho-
mogenization and extraction protocol that has been demonstrated previ-
ously to successfully remove both high and low molecular weight
proteins, such as MMPs, from solid tissue samples.17-19 This method uses
a homogenization process, an extraction buffer, and a centrifugation method
by which a complete uniform yield of intracellular and extracellular protein
is obtained. In brief, a uniform weight (50 mg) of the frozen samples was
placed in ice-cold extraction/homogenization buffer (buffer volume used
was 1:6 w/v, containing 10 mmol/L cacodylic acid pH 5.0, 0.15 mol/L
NaCl, 20 mmol/L ZnCl, 1.5 mmol/L NaN3, and 0.01% Triton X-100 [v/
v]) and allowed to thaw on ice. We18,20 have demonstrated previously
that this approach stabilizes proteins and proteases during the extraction
process. Stainless steel beads (5 mm) were placed in the samples, and the
beads were oscillated at a high frequency (30 Hz; 2 cycles, 5 minutes
each), resulting in full tissue disruption and uniform homogenization (Tis-
sueLyserII, catalog No. 85300; Qiagen NV, Venlo, The Netherlands).
This homogenization approach uses a full cell disruption technique to fully
extract intracellular and extracellular proteins from a solid tissue sample.
The homogenate was then centrifuged (800g, 10 minutes, 4C) (model
5810 or 5417c; Eppendorf AG, Westbury, NY) and the supernatant re-
moved to a fresh tube and stored on ice. Protein concentrations were deter-
mined in duplicate from the final extracts by the Bradford method (Bio-Rad
Protein Assay; Bio-Rad Laboratories, Hercules, Calif) and then titrated to
a uniform protein concentration (100 mg), aliquoted, and stored at80C
until subjected to multiplex suspension array analysis.
Analytical Measurements
The protein titrated samples were thawed on ice and subjected to multi-
plex suspension array (Human Fluorokine MAP MMP Kit, LMP000; R&D
Systems, Inc, Minneapolis, Minn), in which all samples could be measured
in simultaneous fashion, thereby minimizing interassay coefficient of vari-
ation. The titrated samples were subjected to this assay in triplicate, and
these triplicate values were then examined with respect to intra-assay coef-
ficient of variation. For repeated samples that were outside a 15% confi-
dence interval (3 occurrences in the present study), the entire
homogenization and assay were repeated. The multiplex array was previ-
ously validated and calibrated using internal controls for each MMP
type.21 The matrix was assembled to measure representative subtypes
from each class of MMPs that included the collagenases (MMP-1, MMP-
8, and MMP-13), the gelatinases (MMP-2 and MMP-9), the stromelysins/
matrilysins (MMP-3/MMP-7), and the elastases (MMP-12). The relative
fluorescence obtained for each distinct MMP (Bio-Plex 200; Bio-Rad Lab-
oratories) was converted to an absolute concentration using standards thatThe Journal of Thoracic and Cawere included in each assay, and the specifications for each reagent and sen-
sitivity are shown in Table 1. The coefficient of variation for these assays
was 15% or less. For all of the MMP multiplex assays, the sample readings
fell within the targeted dynamic range for the analyte of interest. A represen-
tative standard curve and the sample results for MMP-2 are shown in
Figure 1. All MMP assays were blinded to region, histology, and status
of recurrence.
Data Analysis
The fluorescence emissions for each set of MMP standards were first fit
to a 5-parameter logistic equation (Figure 1), following a conventional for-
mat for nonlinear fluorescence profiles.22 Using this 5-parameter logistic
curve fit, the fluorescence emissions for the samples were converted to ac-
tual MMP values and then finally to MMP content per milligram of wet sam-
ple weight. The comparisons of MMP profiles by region and by histologic
type, pair-wise comparisons, were performed with a t statistic. For the pur-
poses of comparisons of MMP profiles by both region and histologic type,
analysis of variance was performed in which region and histologic type wererdiovascular Surgery c Volume 139, Number 4 985
TABLE 2. MMP content in normal and NSCLC specimens
Region Histologic type
MMP type Normal NSCLC P value AdenoCa Sq Cell Ca P value
Collagenases
MMP-1 1.3  0.9 33.7  10.9 .0025 8.3  2.4 55.7  19.2 .0115
MMP-13 0.1  0.1 7.9  5.3 .0731 1.8  0.6 13.1  9.8 .1347
MMP-8 85.2  10.8 296.4  84.0 .0084 53.3  22.6 506.4  141.9 .0023
Gelatinases
MMP-2 57.3  7.5 161.0  58.8 .0437 79.7  20.3 231.3  107.0 .0888
MMP-9 216.3  24.3 185.5  37.8 .2479 89.5  28.6 268.4  61.4 .0065
Lysins
MMP-3 0.7  0.1 38.6  30.8 .1130 1.3  0.4 70.8  57.1 .1183
MMP-7 7.9  1.5 75.1  15.8 .0001 87.4  23.0 63.5  21.9 .4559
Elastases
MMP-12 1.4  1.2 24.4  6.5 .0006 7.8  2.9 38.7  11.0 .0062
Sample size (n) 41 41 19 22
MMP, Matrix metalloproteinase; NSCLC, non–small cell lung cancer; AdenoCa, adenocarcinoma; Sq Cell Ca, squamous cell carcinoma. MMP types are presented by MMP class.
*Values reported in picograms per milligram wet sample weight.
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tive MMP profiles to recurrence rates, a categorical analysis was performed.
First, the samples were stratified to recurrence or no recurrence and the rel-
ative MMP values compared between these stratifications. Inasmuch as
these data were not normally distributed, a Wilcoxon test was performed.
All statistical procedures were performed with STATA statistical software
(STATA Intercooled version 8.0; Stata, Inc, College Station, Tex). Results
are presented as mean  standard error of the mean.RESULTS
The summary of MMP levels, by region (normal,
NSCLC) and by histologic type, is presented in Table 2.
The MMP types examined were categorized by subgroups
as shown. For the MMP collagenase subgroup, MMP-1
and MMP-8 increased by more than 3-fold. Relative levels
for MMP-13 appeared increased in the NSCLC region,
but owing to a high degree of variation between samples,
this did not reach statistical significance. For the MMPTABLE 3. Analysis of variance results for main effects (region and
histology) and interactions
Region Histology Interaction
MMP type F-statistic P value F-statistic P value F-statistic P value
Collagenases
MMP-1 8.67 .0043 5.58 .0206 4.71 .0330
MMP-13 1.97 .1644 1.11 .2955 1.11 .2961
MMP-8 6.34 .0138 10.16 .0021 6.91 .0103
Gelatinases
MMP-2 2.83 .0966 2.21 .1413 1.18 .2801
MMP-9 0.71 .4037 5.67 .0197 3.07 .0837
Lysins
MMP-3 1.32 .2541 1.30 .2582 1.26 .2653
MMP-7 19.04 .0000 0.34 .5593 0.91 .3444
Elastases
MMP-12 12.45 .0007 7.07 .0095 5.34 .0235
MMP, Matrix metalloproteinase.
986 The Journal of Thoracic and Cardiovascular Surggelatinase subgroup, MMP-2 levels were increased by ap-
proximately 3-fold in the NSCLC region. In the lysin and
the elastase subgroups, MMP-7 and MMP-12, respectively,
were increased by more than 10-fold in the NSCLC region.
Moreover, a different MMP portfolio was observed between
NSCLC histologic types. For example, MMP-1, -8, -9, and
-12 increased by more than 4-fold in squamous cell versus
adenocarcinoma. In light of the fact that MMP levels
changed as a function of region (normal, NSCLC) and histo-
logic type, analysis of variance was performed to identify
main effects and potential interactions (Table 3). From this
analysis, it was demonstrated that a significant region and
histologic type interaction occurred for MMP-1, -8, and
-12, with MMP-9 approaching statistical significance. This
analysis further confirmed the univariate analysis in that
changes in the levels of specific MMP types were affected
by NSCLC as well as by histologic type. Finally, MMP
levels in patients whose tumor did not recur were compared
with MMP concentrations in patients whose tumor did recur
within 3 years (Table 4). Recurrence was evenly divided be-
tween distant and locoregional. From this approach, in-
creased levels for MMP-8 and MMP-9 were observed
within the NSCLC region in those patients with recurrence.DISCUSSION
The MMPs constitute a large family of proteolytic en-
zymes, which were historically considered to have similar
proteolytic portfolios and induction pathways. However, it
is now recognized that specific MMP types can be induced
by an array of biological signaling pathways and biophysical
events and that this induction is not a uniform process.
Moreover, the profile for MMPs, in general, is highly di-
verse, and specific MMPs can exhibit unique biological ef-
fects on extracellular matrix proteins, cell adhesion,
cytokine processing, and cell growth characteristics. Muchery c April 2010
TABLE 4. Recurrence and tumor MMP content*
MMP type No recurrence Recurrence P value
Collagenases
MMP-1 30.3  12.2 43.2  24.4 .5963
MMP-13 1.4  0.4 25.5  19.5 .3977
MMP-8 148.2  37.4 700.4  268.0 .0057
Gelatinases
MMP-2 97.6  18.5 334.1  211.3 .3315
MMP-9 132.0  22.9 331.4  119.4 .0158
Lysins
MMP-3 6.2  2.3 126.7  114.1 .2392
MMP-7 83.7  20.2 50.3  18.0 .6995
Elastases
MMP-12 25.6  8.5 21.0  7.4 .5562
Sample size (n) 30 11
MMP, Matrix metalloproteinase. *Values reported in picograms per milligram wet
sample weight.
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about by past studies that have examined MMP regulation
and expression patterns in cancer, and more specifically
lung carcinoma.1,2,13 However, past clinical studies that
have examined relative MMP expression and/or levels in
lung cancer specimens have focused on one MMP type or
a single class of MMPs.3–12 In addition, past studies have
used semiquantitative approaches or examined MMP levels
in relative terms, rather than in absolute levels. As a conse-
quence, the absolute changes in MMP levels across a wide
spectrum of MMP types and classes in a focused set of
lung cancer specimens, such as NSCLC, remained un-
known. Accordingly, the present study used a quantitative
approach to measure absolute MMP levels from all of the
classes of soluble MMP types in NSCLC and normal lung
samples. The unique findings from this study were 2-fold.
First, a diverse number of MMP types are increased in abso-
lute amounts in NSCLC, and these levels change as a func-
tion of histologic type. Second, the absolute levels for
certain MMP types were increased in samples taken from pa-
tients with tumor recurrence. Taken together, these findings
demonstrate that a full portfolio of MMP types can be con-
sistently measured in NSCLC samples, which may hold both
prognostic and therapeutic relevance.
A number of past studies have successfully isolated RNA
and protein from tumor samples and profiled a limited num-
ber of MMPs.23-26 For example, protein was successfully ex-
tracted from thyroid tumors, and relative MMP-1 and MMP-
9 measurements were performed using a targeted enzyme-
linked immunoassay.27 This past study demonstrated an as-
sociation between higher levels of MMP-1 and MMP-9 to
thyroid histologic type. The present study used a reproduc-
ible protein extraction method and a unique MMP multiplex
approach that allowed for quantification of 8 individual
MMP protein levels simultaneously. Through this quantita-
tive approach, the results demonstrated important differ-
ences in absolute MMP abundance profiles betweenThe Journal of Thoracic and CaNSCLC and normal lung samples, as well as between dis-
tinct NSCLC histologic profiles. For example, absolute
levels of MMPs within the collagenase class (MMP-1, -8,
and -13) increased significantly in NSCLC, and increased
levels of MMP-1 and MMP-8 were particularly pronounced
in squamous cell carcinoma samples. Past studies have iden-
tified that this class of MMPs can play a role in a number of
biological processes relevant to cancer progression, which
includes growth, migration, invasion, apoptosis, and angio-
genesis.1–5,25,26 However, a number of considerations must
be taken into account when evaluating absolute MMP levels
and to what extent these levels may be reflective of changes
in overall proteolytic potential and thereby influencing rele-
vant biological events. In general terms, net MMP proteo-
lytic activity is dependent on transcriptional and
posttranslational events, which include MMP synthesis, se-
cretion, and activation.1,2 The present study demonstrated
that absolute levels of specific MMP types changed in
NSCLC, but it could not differentiate between the proform
and active form of these MMPs. In past immunohistochem-
ical studies, a similar limitation existed whereby changes in
the relative abundance of certain MMP types could be iden-
tified in a tumor specimen, but the activational state of the
MMP could not be discerned.4–7,10,11 Although the net
changes in proteolytic activity could not be determined in
the present study, the absolute changes in MMP levels that
were observed in the NSCLC samples are likely reflective
of changes in upstream induction pathways. Specifically,
MMPs are tightly regulated at the transcriptional level,28,29
in which both ligand and adhesion mediated receptor inter-
actions alter intracellular formation of transcription factors
that specifically bind to regulatory elements within the
MMP promoter region. Thus, the absolute changes in
MMP profiles with NSCLC that were observed in the pres-
ent study are likely the result of altered transcription path-
ways that are reflective of the underlying cancer process.
Indeed, MMP expression profiles have been demonstrated
to be directly associated with the relevant process of tumor
biology, which includes local growth and progno-
sis.1,5,7,11,23,25,26 The present study provides for a proof of
concept that profiling of a large array of MMPs in NSCLC is
possible and could be expanded to reveal specific subsets of
MMPs that hold both diagnostic and therapeutic relevance.
Whereas past studies have examined one or several MMP
types in NSCLC specimens,3–12 these past investigations
have used semiquantitative approaches; therefore, direct
comparisons to the present study are difficult, where abso-
lute protein levels of a full spectrum of MMP types were
quantified in normal and NSCLC regions. However, in gen-
eral, past studies have identified that a relative increase in
MMP-1, -2, -7, and -12 has occurred in NSCLC, consistent
with the current study.3–12 Moreover, in the present study,
a differential MMP profile could be demonstrated between
histologic types of NSCLC, which can be difficult whenrdiovascular Surgery c Volume 139, Number 4 987
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the present study, absolute levels of MMP-9 were increased
in squamous cell carcinoma but not in adenocarcinoma.
A past study by Pinto and associates10 suggests that the in-
creased levels of MMP-9 in this histologic type of NSCLC
can be associated with a poor prognosis. Taken together,
these results suggest that simultaneous quantitative measure-
ments of a full portfolio of MMPs in NSCLC specimens may
provide for distinct tumor profiling and thereby develop spe-
cific thresholds for MMP protein levels for prognostic use.
However, further examination of how MMP profiles differ
between histologic types of NSCLC and are related to
prognosis will be required. Furthermore, the results from
the present study using MMP protein measurements with
a high sensitivity multiplex array will need to be performed
in parallel with histologic studies to provide cell and
spatial information. For example, Thomas and associates11
demonstrated a higher expression of certain MMP types in
adenocarcinoma using morphometric scoring of immuno-
histochemical stained specimens. Furthermore, inasmuch
as the multiplex array provides for a high sensitivity ap-
proach for measuring MMPs in small sample volumes,
then future studies that examine the relationship between
MMP levels in NSCLC samples to that of a simultaneously
obtained plasma sample would be of prognostic relevance.
Indeed, initial studies of profiling of MMPs in a collected
blood sample have shown prognostic potential in several
different cancers.30-35 For example, plasma MMP levels
(particularly MMP-2, -7, and -9) have been studied in a vari-
ety of cancers, including colon cancer,30,31 breast cancer,32
gastric cancer,33 and renal cell carcinoma.34 Moreover, in-
creased circulating MMP-9 levels have been identified in pa-
tients with NSCLC.35 Indeed, the relative increase in plasma
MMP-9 levels reported in this past study parallel the magni-
tude of absolute changes in MMP-9 levels that were ob-
served in the present study with respect to the squamous
cell NSCLC samples. However, these past studies and the
present study only provide associative results, and a prospec-
tive study that simultaneously measures the relationship be-
tween circulating and tumor levels of MMPs in patients with
NSCLC to that of clinical outcomes would be warranted.
The present study measured absolute levels of MMPs in
NSCLC samples and identified that certain MMPs changed
dramatically whereas other MMP types remained unaltered
when compared with normal samples. In addition, the levels
of certain MMP types appeared to be selectively increased in
certain histologic types. Through this type of broad MMP
profiling, it may be possible to identify which MMPs may
be specifically expressed in NSCLC, as well as in a specific
histologic type, and thereby allow for the formation of hy-
pothesis-based, directed pharmacologic studies. Although
MMPs in general have been identified as potential targets
for anticancer pharmacology, the use of broad-spectrum
MMP inhibitors has not met with success.13-16 Postulated988 The Journal of Thoracic and Cardiovascular Surgreasons for the failure of broad-spectrum MMP inhibition
in the context of NSCLC are that inhibition of certain
MMP types that are not contributory to cancer progression
will result in toxic side effects, initiation or progression of
disease, and poor patient outcome. In the present study, ab-
solute levels of MMP-7 were increased by 10-fold in
NSCLC, and this MMP type has been identified for more
specific pharmacologic inhibition in the context of cancer
progression.13,27,36 MMP-7 is one of only a few MMPs ac-
tually secreted by tumor cells. It regulates cell proliferation
and apoptosis by cleaving the ectodomain of heparin bind-
ing–epidermal growth factor precursor.1 MMP-7 cleaves
E-cadherin, a cell-adhesion molecule, and deregulation of
E-cadherin is associated with cancer progression.2 Cleavage
also triggers the epithelial-to-mesenchymal transition. How-
ever, the relationship between the biological function of cer-
tain MMP types and the quantitative measurements
performed in the present study remain associative at best.
Nevertheless, owing to the unique functionality of certain
MMP types and the marked overexpression pattern observed
in the present set of NSCLC specimens, a postulate for fur-
ther study is that pharmacologic regulation of certain MMP
types is required in certain forms of NSCLC and that MMP
profiling would provide a means to tailor pharmacotherapy.
The differential profile observed in the present study and the
diversity of biological functions of different MMP types un-
derscores a likely reason for disappointing results when
broad-spectrum MMP inhibitors were evaluated.14-16,27,36
MMP-2,4,9 MMP-7,5,12 MMP-9,4,6,10 and MMP-127,8
overexpression have been related to poor outcome in pa-
tients with NSCLC. However, different analysis techniques,
semiquantitative analyses, and differing stages and histo-
logic types make comparisons difficult. We found increased
levels of MMP-8 and MMP-9 in patients who had recurrence
within 3 years of surgery compared with those who did not
(Table 4). Overexpression of several MMPs tested (MMP-2,
MMP-3, MMP-9, and MMP-13) have been associated with
epithelial-to-mesenchymal transition, a fundamental biolog-
ical process in which epithelial cells lose their polarity,
cell–cell adhesion, and adopt a mesenchymal morphology
appropriate for migration.1 Tumor staining for MMP-9 in
resected adenocarcinoma of the lung has been shown to be
strongly related to survival.10 In another study, detection
of homogeneous MMP-9 in NSCLC cells was an indepen-
dent prognostic factor for shortened cancer-related survival.6
More patients with recurrence must be studied to ascertain
whether an MMP expression profile can be constructed
that will predict early recurrence of resected adenocarci-
noma and squamous cell carcinoma of the lung.
LIMITATIONS
Several limitations of the present study must be recog-
nized. First, this study quantified MMP types in a small num-
ber of samples from squamous and adenocarcinomaery c April 2010
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a number of relationships between tumor biology and out-
comes. Nevertheless, our preliminary results suggest that
a relationship between recurrence and certain MMP levels
is likely to exist in the context of NSCLC. Second, more
than 26 MMP types have been described, and the present
study therefore only examined a limited number. However,
this study constructed the multiplex array to encompass rep-
resentative MMPs from the major classes of MMP types and
those that have been reported in past NSCLC histologic
studies. Future studies that expand the sample size and
MMP portfolio would be appropriate. Third, a critical con-
trol point of MMP activity is the tissue inhibitors of the
MMPs (TIMPs) and can regulate MMP activity by binding
MMPs in a 1:1 stoichiometry. The biological functions of
the TIMPs are also complex.37 For example, elevated levels
of TIMP-1 have been associated with a poor prognosis in
NSCLC.38,39 Thus, a future study that builds on the MMP
multiplex assay through quantification of the 4 known
TIMPs would be an important future direction. Fourth, this
study measured MMP profiles from whole lung samples,
and therefore the specific cell types and relative MMP distri-
bution throughout the tumor could not be determined.
Nevertheless, the present study demonstrated quantitative
differences in MMP levels of early-stage adenocarcinoma
and squamous cell carcinoma, as well as tumors that have
recurred within 3 years of resection. These new results
underscore the diversity of MMPs in NSCLC and suggest
that profiling this proteolytic system would hold clinical
significance.
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DrDavid R. Jones (Charlottesville, Va). I have only a few ques-
tions for you. You looked only at protein levels of the MMPs. Can
you say what you perceive are some of the pitfalls of looking at
these in isolation in a small sample size, and do you believe that per-
haps looking at messenger RNA levels would add some value to
your analysis?990 The Journal of Thoracic and Cardiovascular SurgDr Shah. Thank you for your question. Yes, we acknowledge
that we do have a small sample size, but our assay is very sensitive
and highly quantifiable even in small samples, as we have previ-
ously shown in cardiovascular studies. We decided to look at the
protein because it is the final effector and, therefore, our focus.
Dr Jones. Second, several groups have shown that MMP-9
levels are predictive of recurrence, much as you have seen here.
I found it interesting that there was no difference in MMP-9 levels
between your normal and your cancerous lung tissue. Do you have
a possible explanation for that?
Dr Shah. The difference may be that semiquantitative methods
were used in previous studies. It is also known that MMP may be
a marker of greater importance in more advanced NSCLC.
DrDaoM.Nguyen (Miami, Fla).You used a tumor homogenate.
It is a mixture of cells from the tumor itself and from the stroma. Are
the MMPs coming from the stroma, like tumor-derived stromal tis-
sues, or are they coming from the cancer cells themselves, or both?
Dr Shah. That is a good question. I honestly could not speculate.
I would assume they are coming from the tumor just because of the
difference between the tumor sample and the normal sample.
Dr Nguyen. It can come from both, actually. You should look
into it. I think laser-capture microdissection can help you with that.
Second question: This is a protein and these are enzymes. Are
you planning to do enzyme assays? A lot of these proteins are
present in small quantity and hard to detect. Do you plan to do
zymograms?
Dr Shah. Possibly in future studies, yes.ery c April 2010
